During the rapid development cycle for Internet products (websites and mobile apps), new features are developed and rolled out to users constantly. Features with code defects or design flaws can cause outages and significant degradation of user experience. The traditional method of code review and change management can be time-consuming and error-prone. In order to make the feature rollout process safe and fast, this paper proposes a methodology for rolling out features in an automated way using an adaptive experimental design. Under this framework, a feature is gradually ramped up from a small proportion of users to a larger population based on real-time evaluation of the performance of important metrics. If there are any regression detected during the rampup step, the ramp-up process stops and the feature developer is alerted. There are two main algorithm components powering this framework: 1) a continuous monitoring algorithm -using a variant of the sequential probability ratio test (SPRT) to monitor the feature performance metrics and alert feature developers when a metric degradation is detected, 2) an automated ramp-up algorithm -deciding when and how to ramp up to the next stage with larger sample size. This paper presents one monitoring algorithm and three ramping up algorithms including time-based, power-based, and riskbased (a Bayesian approach) schedules. These algorithms are evaluated and compared on both simulated data and real data. There are three benefits provided by this framework for feature rollout: 1) for defective features, it can detect the regression early and reduce negative effect, 2) for healthy features, it rolls out the feature quickly, 3) it reduces the need for manual intervention via the automation of the feature rollout process.

As the direct contacting site for pathogens and allergens, the mucosal barrier plays a vital role in the lungs and intestines. Innate lymphoid cells (ILCs) are particularly resident in the mucosal barrier and participate in several pathophysiological processes, such as maintaining or disrupting barrier integrity, preventing various pathogenic invasions. In the pulmonary mucosae, ILCs sometimes aggravate inflammation and mucus hypersecretion but restore airway epithelial integrity and maintain lung tissue homeostasis at other times. In the intestinal mucosae, ILCs can increase epithelial permeability, leading to severe intestinal inflammation on the one hand, and assist mucosal barrier in resisting bacterial invasion on the other hand. In this review, we will illustrate the positive and negative roles of ILCs in mucosal barrier immunity.

No abstract

No abstract